The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Mass spectrometry, NGS & NGF for MRD detection in multiple myeloma
Meral Beksac, MD, Ankara University, Ankara, Turkey, comments on the use of measurable residual disease (MRD) detection techniques including next-generation sequencing (NGS), next-generation flow cytometry (NGF), and mass spectrometry (MS), highlighting some of the advantages of these techniques. Dr Beksac explains that MS is a blood-based MRD assay that can be used in addition to NGS or NGF when a patient is MRD-positive.This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
